ATOS Atossa Therapeutics, Inc.
$2.38▼ -2.86%
Healthcare
Other
Volume 24.8K
Avg Volume (10D) 114.6K
Key Metrics & Fundamentals
Market Cap
$23.75M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.70 - 14.85
% vs 50 MA
-2.52%
% vs 200 MA
-41.31%
RSI-14
46.7
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.70
Free Cash Flow
-$9.64M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$8.69M
COGS
–
Operating Exp
$8.69M
Operating Income
-$8.69M
EBIT
-$8.69M
Pretax Income
-$8.49M
Net Income
-$8.49M
EPS (Diluted)
-0.95
Price & Volume History
Loading chart…
Recent News
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
PR Newswire · Oct 19, 2026 8:00 AM ET
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
PR Newswire · Oct 9, 2026 8:00 AM ET
Atossa plans shareholder stake in potential PRV proceeds
Pharmaceutical Technology · Sep 30, 2026 1:18 PM ET
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
PR Newswire · Sep 29, 2026 8:00 AM ET
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
PR Newswire · Sep 24, 2026 8:00 AM ET
ATOS: Multiple Catalysts Converge in 2H26
Zacks Small Cap Research · Aug 14, 2026 9:22 AM ET
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
PR Newswire · Aug 7, 2026 8:45 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ATOS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.